CN105285980A - 一种红花籽油复方保健喷雾剂及制备方法 - Google Patents
一种红花籽油复方保健喷雾剂及制备方法 Download PDFInfo
- Publication number
- CN105285980A CN105285980A CN201510659270.8A CN201510659270A CN105285980A CN 105285980 A CN105285980 A CN 105285980A CN 201510659270 A CN201510659270 A CN 201510659270A CN 105285980 A CN105285980 A CN 105285980A
- Authority
- CN
- China
- Prior art keywords
- seed oil
- preparation
- care
- health
- spraying agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003813 safflower oil Substances 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 150000001875 compounds Chemical class 0.000 title claims abstract description 11
- 239000003795 chemical substances by application Substances 0.000 title abstract 5
- 238000005507 spraying Methods 0.000 title abstract 5
- 235000019485 Safflower oil Nutrition 0.000 title abstract 3
- 235000005713 safflower oil Nutrition 0.000 title abstract 3
- 210000004369 blood Anatomy 0.000 claims abstract description 22
- 239000008280 blood Substances 0.000 claims abstract description 22
- 239000000463 material Substances 0.000 claims abstract description 16
- 241000241413 Propolis Species 0.000 claims abstract description 13
- 229940069949 propolis Drugs 0.000 claims abstract description 13
- 230000036039 immunity Effects 0.000 claims abstract description 12
- 239000001335 perilla frutescens leaf extract Substances 0.000 claims abstract description 11
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 11
- 230000036772 blood pressure Effects 0.000 claims abstract description 7
- 239000007921 spray Substances 0.000 claims description 14
- 239000003921 oil Substances 0.000 claims description 12
- 235000019198 oils Nutrition 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 10
- 229940041678 oral spray Drugs 0.000 claims description 10
- 239000000668 oral spray Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 6
- 239000012467 final product Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 2
- 230000036541 health Effects 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 23
- 235000013305 food Nutrition 0.000 abstract description 4
- 240000000950 Hippophae rhamnoides Species 0.000 abstract description 2
- 235000003145 Hippophae rhamnoides Nutrition 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract description 2
- 210000000214 mouth Anatomy 0.000 abstract 3
- 230000018109 developmental process Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000009758 senescence Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 16
- 230000037396 body weight Effects 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 230000006870 function Effects 0.000 description 9
- 238000003304 gavage Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 230000009182 swimming Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- -1 oryzanol Natural products 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 238000012449 Kunming mouse Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000002929 anti-fatigue Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 235000021323 fish oil Nutrition 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical group C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 208000033065 inborn errors of immunity Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000031288 Combined hyperlipidaemia Diseases 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 208000007957 amaurosis fugax Diseases 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 229960001770 atorvastatin calcium Drugs 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229940088529 claritin Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002208 flavanones Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 238000012683 free radical ring-opening polymerization Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 206010018388 glossodynia Diseases 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明所述的一种红花籽油复方保健喷雾剂及制备方法,由红花籽油、蜂胶、紫苏籽油、沙棘籽油为纯天然药食同源材料通过常规的口腔喷雾剂制备方法添加辅料制成口腔喷雾剂,利用它们的协同作用,制成提高免疫力、延缓衰老及降低血糖、血脂、血压的功能性保健食品,产品安全、无副作用,具有显著保健功效,可长期服用,具有很好的市场开发前景。
Description
技术领域
本发明提供一种红花籽油复方保健喷雾剂及制备方法,用于提高人体免疫力和延缓衰老,同时还有降血糖、血脂、血压功能,属于保健食品技术领域。
背景技术
免疫系统的主要功能有三个,即免疫防御,免疫监视和免疫自稳定,其作用为抵抗入侵的病毒和外来微生物及其毒性产物的感染和损害,清除机体内的损伤,衰老,变性组织,摧毁机体内的突变,畸变,病毒感染细胞和恶性新生物。机体的免疫与衰老密切相关,衰老的自由基理论提出,人体受新陈代谢作用的影响时刻产生自由基,对机体产生过氧化损伤,但同时机体又存在着有效的自由基清除系统,使体内自由基维持在正常水平。但受现代社会环境压力和生活压力的影响,人体的免疫力在处于下降状态,进而体内自由基极易处于不平衡状态,过量的活性氧和自由基,会引起DNA损伤而引发基因突变,促进生物大分子交联而使其丧失功能等危害,进而加速人体的衰老。
世界卫生组织将机体无器质性病变,但是有一些功能改变的状态称为“第三状态”,也就是我们俗称的“亚健康状态”。有调查表明,我国目前75%以上的人群处于亚健康状态,这部分人群虽然没有器官、组织功能的病症和缺陷,但是却会感觉身体不适,过度疲劳、活力降低、适应力下降,经常处于焦虑、烦躁、头昏脑胀、食欲不振状态。针对这种情况,越来越多的人开始意识到提高免疫力的重要性,因此抗疲劳提高免疫力的保健品的市场需求和市场容量是巨大的,其社会效益和经济效益也无疑是较好的。
发明内容
本发明提供一种红花籽油复方保健喷雾剂,提高人体免疫力和延缓衰老,同时还有降血糖、血脂、血压,清理血管的功能,具有明显的临床疗效。
本发明还公开了一种红花籽油复方保健喷雾剂的制备方法,通过舌下粘膜直接吸收入血液,服用方便,避免被胃酸的分解破坏,也不会被肝脏酶的代谢,保持药效同时也减轻了药物对胃肠道和肝脏的毒副作用。工艺简单、容易操作,生产成本低廉,适用于工业化生产。
本发明所述的一种红花籽油复方保健喷雾剂,其特征在于是由以下药物按重量份数比制成的:
红花籽油25~45、蜂胶10~25、紫苏籽油10~25、沙棘籽油10~25。
本发明所述的一种红花籽油复方保健喷雾剂的制备方法,包括以下步骤:
按比例称取上述原料;红花籽油、紫苏籽油、沙棘籽油混合调配成调和油后,再与蜂胶制成油相混合物,再按常规的口腔喷雾剂制备方法添加辅料制成口腔喷雾剂,即得。
【用法用量】口服;2次/日;10~15ml/次。
【适应症】亚健康,血糖、血脂、血压三高人群,免疫力低下。
本发明的保健作用分析:
红花籽油:含饱和脂肪酸6%,油酸21%,亚油酸73%。由于其主要成分是亚油酸,是食物有种含亚油酸最高的油,还含有大量的维生素E、谷维素、甾醇等药用成分,防止人体血清胆固醇在血管壁里沉积,防治动脉粥样硬化及心血管疾病的医疗保健效果。蜂胶:含有黄酮化合物包括黄酮类、黄酮醇类和双氢黄酮类等,约占蜂胶的4.13%,具有多方面的生理和药理作用,能帮助人体防治多种疾病,使机体各种功能正常化、增强化。蜂胶中的黄酮类化合物,其品种之多、含量之高超过了一般的植物药。对治疗冠心病有效的许多中草药都含有黄酮类化合物。紫苏籽油:是一种高不饱和度的天然油脂,对降低胆固醇、降低血脂、防止动脉粥样硬化、降低脑血栓和心血管疾病的发生有持久作用。α-亚麻酸摄入人体后在酶的作用下可以在人体内转化成二十碳5烯酸(EPA)和二十二碳6烯酸(DHA),它就是深海鱼油的主要成份,因此又叫植物深海鱼油,比深海鱼油更好的是它不含胆固醇,EPA和DHA具有降血脂和提高记忆力的作用。沙棘籽油:棕黄色到棕红色透明油状液体,集沙棘有效成分为一体的高度浓缩物。内含黄酮、有机酸、生物碱、甾醇类、三萜烯类及各种维生素等140多种生物活性成分。具有抗氧化、抗疲劳、护肝、降血脂作用。本发明以红花籽油为主,稳定安全,具有人体免疫力和延缓衰老功能,加入紫苏籽油、沙棘籽油和蜂胶协同配伍增强了这种功效,且使脂肪酸比例符合营养学标准,防止某些由于油脂摄入不平衡引起的慢性病,可降低动脉硬化的发生。上述各药相互作用,可以补气补血,升阳解肌,生津止渴,活血调经,补中益气,可显著提高机体器官功能,快速恢复体力和精力,与本发明主方各药合用,进一步增强抗疲劳的功效。
提供以下试验表明本发明的保健医疗作用
实施例1
对细胞免疫活性的作用
1实验材料与方法
1.1实验材料
实验动物,采用4周龄的昆明小鼠,体重20±2g,饲养在12h白天/黑夜循环的条件下,温度湿度适宜,喂食标准的颗粒饲料,自由摄食和饮水。本发明保健品(如实施例1~实施例3)由本实验室制备。
1.2实验方法
1.2.1分组:选健康小鼠60只,雌雄各半,分为5组,每组12只。一组为空白对照组,灌胃生理盐水10ml/kg,一组为阳性对照组,灌胃安利纽崔莱蛋白粉50mg/kg,另三组为实验组,灌胃实施例1~实施例3的本发明保健品,分别为120mg/kg,80mg/kg和40mg/kg。
1.2.2MTT实验:将小鼠按1.2.1分组后按每10g体重0.2mL灌胃,每天2次,持续灌胃30天,第31天无菌取脾,于无菌Hank液中制成细胞悬液,200目筛网过滤,Hank液洗3次。用RPMl1640培养液调整细胞浓度为3×106个/mL。而后分两孔加入24孔培养板,每孔1.0mL,一孔加ConA液50μL,一孔作对照,置5%CO2、37℃培养72h。培养结束前4h,每孔吸去上清液0.7mL,加入不含小牛血清的RPMI1640培养液和MTT(5mg/mL,每孔50μL),培养结束后,每孔加入二甲基亚砜200μL,测其在630nm下的吸光度(OD值)。实验结果:
表1不同组对细胞免疫力活性的影响
分组 | 平行1组 | 平行2组 | 平行3组 |
空白对照组 | 0.465±0.082 | 0.454±0.111 | 0.451±0.091 |
阳性对照组 | 0.703±0.112 | 0.698±0.112 | 0.712±0.121 |
实施例1 | 0.544±0.091 | 0.553±0.089 | 0.554±0.097 |
实施例2 | 0.642±0.097 | 0.635±0.104 | 0.624±0.101 |
实施例3 | 0.745±0.121 | 0.737±0.168 | 0.732±0.102 |
结果:本实验本发明保健品高中低剂量组都有提高淋巴细胞免疫力的效果,且高剂量组的效果较阳性对照组还要好些。本发明具有辅助提高细胞免疫力的作用。
实验例2
本发明保健品对小鼠胸腺、脾脏质量的影响
2实验材料与方法
2.1实验材料
实验动物,采用4周龄的昆明小鼠,体重20±2g,饲养在12h白天/黑夜循环的条件下,温度湿度适宜,喂食标准的颗粒饲料,自由摄食和饮水。本发明保健品(如实施例2)由本实验室制备。
2.2实验方法
2.2.1分组:选健康小鼠60只,雌雄各半,分为5组,每组12只。一组为空白对照组,灌胃生理盐水10ml/kg,一组为阳性对照组,灌胃安利纽崔莱蛋白粉80mg/kg,另三组为实验组,灌胃本发明实施例1~3保健品80mg/kg。
2.2.2实验
分别设置本发明保健品实施例1~实施例3三个浓度组,以及一个空白对照组(以蒸馏水为对照),和阳性对照组,经口给予小鼠不同剂量的鹿脾提取物30天后,与对照组小鼠比较胸腺、脾脏质量的差异。
2.3实验结果:
表2不同的设置组对小鼠胸腺、脾脏质量的影响
分组 | 胸腺/体重比值/(mg/g) | 脾脏/体重比值/(mg/g) |
空白对照组 | 1.86±0.51 | 5.12±0.97 |
阳性对照组 | 2.32±0.78 | 5.64±0.76 |
实施例1 | 2.09±0.84 | 5.43±0.75 |
实施例2 | 2.12±0.65 | 5.67±0.82 |
实施例3 | 2.31±0.56 | 5.76±0.78 |
结果:从实验数据中可以看出,本发明实施例1~实施例3组都有提高小鼠胸腺、脾脏/体重比值的效果。本发明具有辅助提高免疫力的作用。
实验例3
本发明保健品对小鼠体内MDA,SOD和GSH-Px水平变化情况
3实验材料与方法
3.1实验材料
实验动物,采用4周龄的昆明小鼠,体重20±2g,饲养在12h白天/黑夜循环的条件下,温度湿度适宜,喂食标准的颗粒饲料,自由摄食和饮水。本发明保健品(如实施例2)由本实验室制备。
3.2实验方法
3.2.1分组:选健康小鼠48只,雌雄各半,分为4组,每组12只。一组为红花籽油对照组,另三组为实验组,灌胃实施例1~实施例3三种本发明保健品80mg/kg。
3.2.2实验
分别设置本发明实施例1~实施例3三个组,以及红花籽油对照组(以单方红花籽油为对照),经口给予小鼠不同剂量的本发明保健品30天后,与对照组小鼠比较血清中MDA,SOD和GSH-Px的水平变化。
3.3实验结果:
表3不同的设置组对小鼠血清中MDA,SOD和GSH-Px的水平的影响:
结果:从实验数据中可以看出,本发明保健品实施例1~实施例3组都可以降低小鼠血清中的MDA含量,提高血清中SOD和GSH-Px的水平,说明本发明可以减少小鼠体内的氧自由基,提高抗氧化活性,进而说明本发明具有辅助延缓衰老的效果。同时说明本发明组方通过协同作用比单方红花籽油具有更好的临床效果。
实施例4
负重游泳实验
末次给药30min后,置小鼠于恒温游泳箱中游泳,水深20cm,水温23℃,小鼠尾根部捆绑5%体重的铝块,记录小鼠从开始游泳到死亡的时间(s),结果如表4所示:
表4小鼠负重游泳时间结果
由上表可见,与生理盐水组相比较,本发各保健品制剂组均可以显著增加小鼠负重游泳的时间,并且P<0.05,说明该结果具有统计学意义。同时说明本发明组方通过协同作用比单方红花籽油具有更好的临床效果。
本发明的积极效果在于:红花籽油、蜂胶、紫苏籽油、沙棘籽油为纯天然药食同源材料,利用它们的协同作用,制成提高免疫力、延缓衰老及降低血糖、血脂、血压的功能性保健食品,产品安全、无副作用,具有显著保健功效,可长期服用,具有很好的市场开发前景。
具体实施方式
通过以下实施例进一步举例描述本发明,并不以任何方式限制本发明,在不背离本发明的技术解决方案的前提下,对本发明所作的本领域普通技术人员容易实现的任何改动或改变都将落入本发明的权利要求范围之内。
实施例1
称取红花籽油25g、紫苏籽油10g、沙棘籽油10g混合调配成调和油后,再与蜂胶10g制成油相混合物,再按常规的口腔喷雾剂制备方法添加辅料制成口腔喷雾剂,即得。
实施例2
称取红花籽油35g、紫苏籽油15g、沙棘籽油15g混合调配成调和油后,再与15g蜂胶制成油相混合物,再按常规的口腔喷雾剂制备方法添加辅料制成口腔喷雾剂,即得。
实施例3
称取红花籽油45g、紫苏籽油25g、沙棘籽油25g混合调配成调和油后,再与蜂胶25制成油相混合物,再按常规的口腔喷雾剂制备方法添加辅料制成口腔喷雾剂,即得。
为表明本发明药物的治疗效果,精选以下几例免疫力低下和亚健康,血糖、血脂、血压三高的患者,服用本发明药品进行治疗,经临床观察进行分析总结如下:
病例1
某女,45岁。自述2010年每年秋来,经常出现感冒,鼻塞。打喷嚏,咽喉痒,全身乏力。查体:舌淡,苔薄白,脉沉浮。初诊:过敏性鼻炎(鼻渊)。经常服用抗过敏药物,抗感冒药物,病情时好时坏,经服本发明实施例1制备喷雾剂的3个疗程,该患者免疫功能增强了,感冒减少了,喷嚏也不打了,基本上达到了痊愈的标准。
病例2
某女,61岁。自述2013年来经常全身倦怠乏力,眼花,两目干涩,心悸,多梦,健忘,神疲,手足发麻。查体:舌淡,苔薄白,脉细无力。诊为血虚证,经常服用补血剂,疗效不显,后服用本发明实施例2保健品3个疗程,逐渐上述症状悉愈。至今身体状况较好。
病例3
某男,39岁。2009年初诊,自述经常感冒,全身乏力,少气懒言,精神疲惫。查体:舌质淡嫩,脉虚。诊为气虚证。服用很多补药,疗效不显,后服用本发明实施例1喷雾剂3个疗程,上述症状明显改善,至今身体状况良好。
病例4
某男,50岁。患者2年前劳累后出现头晕,伴头胀痛,头重脚轻感,伴恶心无呕吐,伴耳鸣,无视物旋转,无一过性黑,休息后症状无明显减轻,遂至医院就诊。既往病史:混合型高脂血症病史2年,确诊后,曾间断服用辛伐他汀、阿托伐他汀钙等药物降脂,现未规律服药,血脂控制不佳;饮食偏咸,油脂较大,否认烟酒嗜好。后服用本发明实施例3喷雾剂3个疗程,上述症状明显改善,至今身体状况良好。
病例5
某男,32岁,身高1.73米、体重80公斤,在一家广告公司做文案。每天坐位活动长达10至12小时,基本不运动,也不控制膳食。体检时发现,血甘油三酯、胆固醇超过正常值,并有中度脂肪肝,体脂占体重30%。后服用本发明实施例2喷雾剂3个疗程以后,体重76.5公斤、体脂25%,血甘油三酯降至正常,胆固醇降低,最大吸氧量增至43毫升/公斤体重/分。
病例6
某男,45岁,身高1.63米、体重82公斤,设计师,做文案工作。每天长时坐位,基本不运动,也不控制膳食。体检时发现,血甘油三酯、胆固醇超过正常值,并有中度脂肪肝,体脂占体重35%。后服用本发明实施例1喷雾剂3个疗程以后,体重75.5公斤、体脂26%,血甘油三酯降至正常,胆固醇降低,最大吸氧量增至44毫升/公斤体重/分。
Claims (3)
1.一种红花籽油复方保健喷雾剂,其特征在于是由以下药物按重量份数比制成的:
红花籽油25~45、蜂胶10~25、紫苏籽油10~25、沙棘籽油10~25。
2.权利要求1所述的一种红花籽油复方保健喷雾剂的制备方法,包括以下步骤:
按比例称取上述原料;红花籽油、紫苏籽油、沙棘籽油混合调配成调和油后,再与蜂胶制成油相混合物,再按常规的口腔喷雾剂制备方法添加辅料制成口腔喷雾剂,即得。
3.权利要求1所述的红花籽油复方保健喷雾剂在提高免疫力、延缓衰老及降低血糖、血脂、血压的医用用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510659270.8A CN105285980B (zh) | 2015-10-14 | 2015-10-14 | 一种红花籽油复方保健喷雾剂及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510659270.8A CN105285980B (zh) | 2015-10-14 | 2015-10-14 | 一种红花籽油复方保健喷雾剂及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105285980A true CN105285980A (zh) | 2016-02-03 |
CN105285980B CN105285980B (zh) | 2017-12-01 |
Family
ID=55184490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510659270.8A Active CN105285980B (zh) | 2015-10-14 | 2015-10-14 | 一种红花籽油复方保健喷雾剂及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105285980B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100998406A (zh) * | 2006-12-18 | 2007-07-18 | 东北虎药业股份有限公司 | 增强免疫力、对胃粘膜损伤有保护功能的保健食品及其制备方法 |
CN101797282A (zh) * | 2010-04-07 | 2010-08-11 | 扬州大学 | 一种新型复方蜂胶制剂及其制备方法 |
WO2010149815A1 (es) * | 2009-06-26 | 2010-12-29 | Olifarma, S.L. | Aceites funcionales a base de aceite de oliva |
CN102907677A (zh) * | 2012-11-14 | 2013-02-06 | 甘肃省轻工研究院 | 辅助降血脂功能的沙棘紫苏油软胶囊及其制备方法 |
CN103815395A (zh) * | 2013-12-25 | 2014-05-28 | 伊犁百信草原蜂业有限责任公司 | 蜂胶与红花籽油软胶囊及其制备方法 |
-
2015
- 2015-10-14 CN CN201510659270.8A patent/CN105285980B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100998406A (zh) * | 2006-12-18 | 2007-07-18 | 东北虎药业股份有限公司 | 增强免疫力、对胃粘膜损伤有保护功能的保健食品及其制备方法 |
WO2010149815A1 (es) * | 2009-06-26 | 2010-12-29 | Olifarma, S.L. | Aceites funcionales a base de aceite de oliva |
CN101797282A (zh) * | 2010-04-07 | 2010-08-11 | 扬州大学 | 一种新型复方蜂胶制剂及其制备方法 |
CN102907677A (zh) * | 2012-11-14 | 2013-02-06 | 甘肃省轻工研究院 | 辅助降血脂功能的沙棘紫苏油软胶囊及其制备方法 |
CN103815395A (zh) * | 2013-12-25 | 2014-05-28 | 伊犁百信草原蜂业有限责任公司 | 蜂胶与红花籽油软胶囊及其制备方法 |
Non-Patent Citations (2)
Title |
---|
李加兴等: "多烯酸植物油及其保健功效研究进展", 《食品科学》 * |
黄世敬: "《轻松降血脂》", 31 March 2015, 金盾出版社 * |
Also Published As
Publication number | Publication date |
---|---|
CN105285980B (zh) | 2017-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017101878A4 (en) | Gynostemma pentaphyllum containing health care pharmaceutical composition for preventing hyperlipidemia, hypertension, hyperglycemia, and gout | |
CN105233010A (zh) | 一种补肾壮阳酒及其制备方法 | |
CN103750339A (zh) | 雪莲培养物保健食品及其用途 | |
US20110189319A1 (en) | Lifeforce liquid supplement | |
CN101411488A (zh) | 人参果茶 | |
CN104799286B (zh) | 一种用于提高免疫力的组合物及其制备方法 | |
CN102659917A (zh) | 一种从松花粉中分离制备粗蛋白及酶解肽类的方法 | |
CN107007646A (zh) | 一种辅助防治癌症的营养复合物 | |
CN105477100A (zh) | 一种灵芝孢子油复方保健喷雾剂及制备方法 | |
CN104388236A (zh) | 一种葡萄酒及其制备方法与应用 | |
CN106236927A (zh) | 一种具有增强免疫力和抗疲劳作用的中药组合物及其制备方法与用途 | |
CN105664140A (zh) | 一种糖肽组合物及其制备方法和用途 | |
CN103238757B (zh) | 一种含发酵棉粕的蛋鸡配合饲料及其制备方法 | |
CN104489172A (zh) | 一种提高免疫力的刺五加保健茶及其制备方法 | |
CN105394750A (zh) | 一种沙棘籽油复方功能保健品 | |
CN111387345A (zh) | 一种复合多糖组合物及其制备方法 | |
CN102552562A (zh) | 一种增强免疫力、延缓衰老功能的保健药物配方 | |
CN104799289A (zh) | 具有抗肿瘤提高免疫功能的复合营养食品及其生产方法 | |
CN105285980B (zh) | 一种红花籽油复方保健喷雾剂及制备方法 | |
CN106819223A (zh) | 一种保健奶茶及其制备方法 | |
CN102205010A (zh) | 一种具有辅助降血脂功能的药物组合物 | |
CN105285977A (zh) | 一种具有抗衰老、提高免疫力功效的保健品 | |
Milind et al. | A Review on Aloe vera. | |
CN104273529B (zh) | 火龙果片 | |
CN107970437A (zh) | 虫草克癌基因肽 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |